Notice of Patent Acquisition for R-SAT, a Distribution Management and Administration Schedule Support System for Regenerative Medicine Products, Jointly Developed with Suzuken Co., Ltd.
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement
Notice regarding completion of approval filing for Japan SB623 chronic TBI program
SanBio Joins the Newly Formed National TBI Registry Coalition (NTRC) as a Founding Member Organization
Business Partnership for Development and Commercialization of Medical Device Implant utilizing MSC2 for the regeneration of esophageal tissue in humans
Publication Comparing Outcome Measures for Persons with Chronic Traumatic Brain Injury in Expert Review of Neurotherapeutics
Presentation of STEMTRA Phase 2 Trial Results at the 44th Annual Meeting of the Japan Society of Neurotraumatology
Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology
The status of domestic approval filing for regenerative cell medicine SB623 for treatment of chronic effects associated with traumatic brain injury
Hiroyasu Narita Joins SanBio as the Head of Clinical Development
